Recurrence Patterns and Clinical Management after a Positive Sentinel Node Biopsy in Melanoma Patients.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2023-12-01 Epub Date: 2024-01-02 DOI:10.1080/07357907.2023.2283459

Jacqueline N de Menezes, Dante A S M Arra, Matheus M Lôbo, Clovis A L Pinto, João P S N Lima, Milton J B Silva, João P Duprat Neto, Eduardo Bertolli

引用次数: 0

Abstract

Introduction melanoma patients who become stage III after a positive sentinel node biopsy (SNB) may have several patterns of recurrence patients and methods retrospective analysis of melanoma patients who have undergone SNB in a single institution from 2000 to 2015. Results There were 111 recurrences (45.1%) among 246 (20.3%) SNB positive patients and median DRFS was 77.7 months. After initial treatment, further recurrences occurred in 68 (77.3%) patients, regardless the site of initial recurrence conclusions multimodal strategies are recommended to achieve better results when managing stage III melanoma patients after a positive SNB.

查看原文本刊更多论文

黑色素瘤患者前哨淋巴结活检阳性后的复发模式和临床管理。

在前哨淋巴结活检(SNB)阳性后进入III期的黑色素瘤患者可能有几种复发模式，患者和方法对2000年至2015年在同一机构接受SNB的黑色素瘤患者进行回顾性分析。结果246例(20.3%)SNB阳性患者中有111例(45.1%)复发，中位DRFS为77.7个月。在初始治疗后，68例(77.3%)患者发生了进一步复发，无论初始复发部位如何。结论:在治疗SNB阳性的III期黑色素瘤患者时，推荐采用多模式策略以获得更好的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.